Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease

NCT04002830 is registered in ClinicalTrials.gov with Ari Zimran as lead sponsor.

NCT NCT04002830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04002830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease
Lead sponsor
Ari Zimran
Phase
Phase 4
Overall status
Completed
Start date
November 20, 2020
Completion date
July 30, 2023
Enrollment
14 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease, type 3